An open-label, Phase II randomised trial of Lapatinib (TYKERB™) + Pemetrexed (Alimta) versus Pemetrexed in the Second Line Treatment of advanced or metastatic Non Small Cell Lung Cancer.

Trial Profile

An open-label, Phase II randomised trial of Lapatinib (TYKERB™) + Pemetrexed (Alimta) versus Pemetrexed in the Second Line Treatment of advanced or metastatic Non Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2012

At a glance

  • Drugs Lapatinib (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 09 Oct 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top